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ABSTRACT
Background Accelerated partner therapy (APT) is a
promising partner notiﬁcation (PN) intervention in
specialist sexual health clinic attenders. To address its
applicability in primary care, we undertook a pilot
randomised controlled trial (RCT) of two APT models in
community settings.
Methods Three-arm pilot RCT of two adjunct APT
interventions: APTHotline (telephone assessment of
partner(s) plus standard PN) and APTPharmacy
(community pharmacist assessment of partner(s) plus
routine PN), versus standard PN alone (patient referral).
Index patients were women diagnosed with genital
chlamydia in 12 general practices and three community
contraception and sexual health (CASH) services in
London and south coast of England, randomised
between 1 September 2011 and 31 July 2013.
Results 199 women described 339 male partners, of
whom 313 were reported by the index as contactable.
The proportions of contactable partners considered
treated within 6 weeks of index diagnosis were
APTHotline 39/111 (35%), APTPharmacy 46/100 (46%),
standard patient referral 46/102 (45%). Among treated
partners, 8/39 (21%) in APTHotline arm were treated via
hotline and 14/46 (30%) in APTPharmacy arm were
treated via pharmacy.
Conclusions The two novel primary care APT models
were acceptable, feasible, compliant with regulations
and capable of achieving acceptable outcomes within a
pilot RCT but intervention uptake was low. Although
addition of these interventions to standard PN did not
result in a difference between arms, overall PN uptake
was higher than previously reported in similar settings,
probably as a result of introducing a formal evaluation.
Recruitment to an individually randomised trial proved
challenging and full evaluation will likely require service-
level randomisation.
Trial registration number Registered UK Clinical
Research Network Study Portfolio id number 10123.
INTRODUCTION
Across England, reported diagnoses of genital
Chlamydia trachomatis continue to rise1 with almost
60% of all chlamydia in people under 25 years
diagnosed in community settings1 where partner
notiﬁcation (PN) services may not be routinely avail-
able. Improving the effectiveness of PN, the process
of identifying exposed sex partners and offering
them testing and treatment2 3 may have a greater
impact on control of chlamydia than widening access
to testing.4 5 However, the optimal PN strategy for
people with chlamydial infection is unknown. A
recent systematic review3 suggests that expedited
partner therapy (EPT),6 in which the doctor provides
the index patient antibiotics or a prescription to give
to their sex partner is more effective than simple
patient referral (verbal advice that the partner(s)
should attend) in preventing index reinfection, and
achieves treatment of a higher proportion of sex part-
ners.7 However, although EPT did not appear to be
more effective than enhanced patient referral (simple
patient referral supplemented by written advice,
longer verbal explanation and or internet resources)
in preventing index reinfection, EPT did achieve a
higher proportion of sex partners reported treated,
although evidence is limited.5
UK prescribing guidance does not support EPT in
this form as it does not include clinical assessment of
the sex partner.8 Accelerated partner therapy (APT),
an adaptation of EPT using health adviser
telephone-led and pharmacist-led PN interventions,
includes a clinical assessment of the sex partner, does
meet UK prescribing guidance and has shown
promise in specialist settings.8–10 Modelling studies
suggest that APT could play an important role in
reducing index reinfection and prevention of repro-
ductive health consequences especially in women, by
reducing the time to successful partner treatment.5 7
PN is known to be problematic in primary
care11–14 but achievable within a chlamydia screen-
ing trial.15 General practitioners (GPs) report bar-
riers to effective PN including lack of knowledge,
skills, time and organisational issues.13 16–18
Although GPs appear to be broadly supportive of
APT,16 it may not directly translate to primary care
settings in which staff are less skilled in sexual
health, and service users may be different from
those attending specialist services.
We aimed at assessing the feasibility, acceptability
and preliminary evidence of effectiveness of APT
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for women diagnosed with chlamydia in non-specialist settings,
through a pilot randomised controlled trial (RCT) of APT in
contrasting primary care services in England. An economic
evaluation is reported in detail elsewhere.19
METHODS
We carried out a three-arm pilot individually-randomised con-
trolled trial of two APT interventions: APTHotline (telephone
assessment of partner(s) by a health advisor plus standard PN)
and APTPharmacy (community pharmacist assessment of
partner plus standard PN), versus standard PN alone (patient
referral) with one-to-one allocation. We deﬁned standard care as
the method of PN in routine use within each service. In prac-
tice, this varied between simple and enhanced patient referral,
depending on the service and healthcare professional involved.
Participants were women aged at least 16 years, diagnosed in
primary care with genital C. trachomatis infection (index
patients) and at least one untreated contactable male sex partner
in the last 6 months. Exclusion criteria for index patients were
known HIV positive status, co-infection with other sexually
transmitted infections (STIs) and an inability to understand
English. Exclusion criteria for male sex partners were symptoms
of complicated infection, allergy or contraindications to azithro-
mycin and an inability to understand English as this precludes a
safe telephone clinical assessment.
The trial took place between 1 September 2011 and 31 July
2013 in inner East London (deprived, young, ethnically mixed
population: six general practices, two community (non-specialist)
contraception and sexual health (CASH) services, ﬁve pharma-
cies) and the south coast of England (non-metropolitan popula-
tion: six general practices, one CASH service, nine pharmacies).
We chose general practices and CASH services with the
highest chlamydia screening and positivity rates and selected
pharmacies based on their proximity to good transport links,
ensuring broad geographical coverage around each recruitment
site. If services devolved management of positive chlamydia
cases to their local National Chlamydia Screening Programme,
we approached the relevant ofﬁce.
Index patients were recruited by healthcare professionals
(practice nurses, GPs and CASH service health advisers) trained
in the study procedures. They identiﬁed patients at the time of
treatment and sought consent to participate. Male sexual part-
ners were recruited by research health advisers on the
APTHotline, or community pharmacists (depending on random-
isation) who explained the study and sought informed consent.
People who did not accept the offer of the trial were managed
according to the service’s routine practice.
Interventions
All index patients were offered standard PN irrespective of the
arm (ﬁgure 1). Therefore, index patients randomised to APT
options were offered APT in addition to standard PN for all of
their partners. During the PN discussion with the index patient,
the health professional entered data directly onto the web tool
and the web tool randomised the index patient’s sexual partners
to one of the three arms. If an APT arm was allocated, the web
tool simultaneously sent an SMS (text message) to the index
patient with a unique personal identiﬁcation number (PIN). The
healthcare professional asked the index patient to talk to her
partner(s) about their need for testing and treatment and to
forward them the PIN as this was required to access
APTHotline or APTPharmacy treatment. If the index patient
was allocated to standard care she did not receive an SMS
message.
We reﬁned the web tool used in a previous study9 to support
the APT patient pathway in primary care, described in detail
elsewhere.19
Outcome measures and ascertainment of outcomes
The primary outcome was whether each contactable partner
(reported as contactable by the index at initial consultation) was
treated within 6 weeks of index diagnosis. This was either
partner veriﬁed by the partner calling the APTHotline or
attending the APTPharmacy, or reported by the index at a
follow-up telephone assessment conducted by health advisers 4–
6 weeks after index treatment. Partners for whom treatment
information was unavailable were considered untreated.
Secondary outcome measures were determined either for the
index or for each partner and included whether the partner was
notiﬁed, partner uptake and acceptability of PN modalities,
number of partners treated per index patient, number of part-
ners notiﬁed per index patient, time to partner treatment and C.
trachomatis reinfection/persistence rates in index patients. For
treated partners we also report the PN method leading to treat-
ment (standard, APTHotline, APTPharmacy, other). We also
collected data on resource use to inform our health economics
evaluation, reported elsewhere.19
To determine reinfection/persistence, 4–6 weeks after treat-
ment we sent index patients who could be reached for tele-
phone follow-up and who agreed a urine collection kit for C.
trachomatis nucleic acid ampliﬁcation test (NAAT) testing, for
posting to the study laboratory.
Process evaluation
We monitored recruitment processes by observing clinical staff
in study sites and conducted informal interviews with a range of
clinicians involved with the study. We explored issues of accept-
ability and preference by undertaking qualitative telephone
interviews with a sample of index patients and their sex part-
ners, on which we conducted a preliminary thematic analysis,
reported elsewhere.19
Sample size
The study was designed as a pilot trial to provide estimates for a
deﬁnitive trial, in line with the Medical Research Council frame-
work for development of complex interventions20 with random-
isation of index patients on an individual basis, recognising that
there would be clustering of partners by index patient. The unit
of analysis was the individual male partner. We assumed that
25% of male partners would be reported (by index or health-
care service) as treated via routine PN in primary care in com-
parison with 40% of male partners who would be reported as
treated via either of the APT options, and sought 80% power.
A 2% signiﬁcance level was chosen (to take account of the need
to make comparisons across three arms (routine, APTHotline,
APTPharmacy)), and a 10% design effect (to take account of
clustering of an average of 1.5 male partners per female index
patient).
We therefore aimed at recruiting 400 index patients across the
two geographical areas over 24 months. However, as recruit-
ment rates were lower than anticipated, a pragmatic decision
was made during the trial to seek full outcome data (including
secondary outcomes from index follow-up interviews) for at
least 200 partners in total across study arms.
Randomisation
Index patients were randomised in a 1:1:1 ratio to one of the
three study arms, by simple computer-generated unrestricted
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randomisation within the web tool. The randomisation applied
to all contactable partners identiﬁed by the index. It was not
feasible for participants or researchers to be blind to the inter-
vention type during implementation or evaluation.
Statistical analyses
Analysis was by intention to treat and blinded. For the primary
outcome, all partners not reported as treated were analysed as if
untreated. Proportions of partners considered treated, consid-
ered untreated and treatment status unknown (by whether index
was followed-up or not) are also reported.
We used logistic regression to calculate adjusted ORs compar-
ing both APTHotline and APTPharmacy with routine PN. ORs
were calculated adjusting for the age and ethnic group of the
index patient. The analysis of outcomes determined for each
partner, such as the primary outcome, was based on robust SEs
to acknowledge the clustering of partners by index. All analysis
was conducted in Stata V.13.
RESULTS
Of 357 chlamydia-positive women screened for eligibility, 49
were found not to be eligible, 67 declined to participate and 42
were not included for other reasons (ﬁgure 2). A total of 199
index patients were randomised, who in total identiﬁed 313
contactable partners.
As all partners not known to be treated were considered to be
untreated there was no loss to follow-up for the primary outcome.
However, some secondary outcomes were obtained from the
index telephone follow-up which failed to occur (index designated
unreachable after three attempts) for roughly a quarter of index
patients (53 of 199) and affecting 87 partners (28% of 313).
Baseline characteristics were similar across arms. The median
age of index patients was 21 years, with a mean of 1.7 sexual
partners over the last 6 months, of whom a mean of 1.6 were
stated to be contactable (table 1).
The proportion of partners known to have been treated
varied little between arms (39% APTHotline and 46% in each
other arm) (table 2) and there was little evidence of difference
between APT intervention and standard patient referral. The
slightly lower proportion known treated in the APTHotline arm
may reﬂect a higher proportion for whom treatment status was
unknown (60% vs 44% Standard and 47% APTPharmacy). The
mean number (SD) of sexual partners known treated per index
by randomisation arm was Standard 0.7 (0.58), APTHotline 0.6
Figure 1 Interventions and clinical management pathways. Accelerated partner therapy (APT) pack—contained prepackaged azithromycin 1 g,
condoms, chlamydia information leaﬂet, a urine sample collection kit for Chlamydia trachomatis nucleic acid ampliﬁcation test (NAAT) with
instructions to provide the sample before taking the antibiotics, prepaid postal envelope and packaging for returning the sample to the study clinic,
and a patient information leaﬂet about the study. APTHotline—sex partner undergoes telephone consultation and invitation for future clinic based
HIV and syphilis screening with research health adviser. Sex partner or his representative collects APT Pack from clinic reception. Sex partner posts
back his completed C. trachomatis NAAT urine sample kit (contained in the APT pack). Results and future clinical care are managed by specialist
clinic. APTPharmacy—sex partner undergoes consultation and invitation for future clinic-based HIV and syphilis screening with sexual health trained
community pharmacist. Pharmacist gives sex partner APT pack at the time of consultation, based on a patient group direction (PGD) which is a legal
framework that allows some healthcare professionals to supply a speciﬁed medicine to a predeﬁned group of patients without a doctor assessment.
Sex partner posts back his completed C. trachomatis NAAT urine sample kit (contained in the APT pack). Results and future clinical care are
managed by specialist clinic. Standard Partner notiﬁcation (PN) (control). For the purposes of this study we deﬁne standard PN as the healthcare
professional advising the index patient to notify his/her sex partner of the need for treatment (simple patient referral). In the contraception and
sexual health (CASH) services this was supplemented by written information about chlamydia and the provision of details of local sexual health
services to the index patient to give to her sex partner (enhanced patient referral). GUM, genitourinary medicine.
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(0.74), APTPharmacy 0.7 (0.70). Among partners randomised
to APTHotline, only 21% were treated via the hotline, and of
those randomised to APTPharmacy, 30% were treated via a
pharmacy (table 2).
Secondary outcomes
Time to partner treatment
The median time (IQR) from index diagnosis to partner treat-
ment was 0 (0–0 days) for routine PN, 0 (0–0 days) for
APTHotline (p=0.78) compared with routine and 0 (0–4 days)
for APTPharmacy (p=0.02) compared with routine.
Index patient reinfection/persistence
Only 38/199 index patients (19% of total) returned a postal
urine sample for reinfection/persistence and chlamydia positivity
was 15% (2/13) in the standard arm, 0% (0/15) in the hotline
arm and 10% (1/10) in the pharmacy arm.
Sex partner testing
In the standard arm no partners were reported to have had a
chlamydia or gonorrhoea test by the index patients, compared
with 4% (4/111) in the APTHotline arm (one of whom had a
positive chlamydia test) and 6% (6/100) in the APTPharmacy
Figure 2 Consort diagram of participants through the trial.
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Table 1 Characteristics of index patients and sexual partners by randomisation arm
Index patients
Arm: characteristic
Standard
N=66
APTHotline
N=68
APTPharmacy
N=65
Total
N=199
Age in years, median (IQR) 20 (19–22) 21 (18–23) 21 (19–24) 21 (19–23)
Ethnicity, % (n)
White British 59 (39) 53 (36) 57 (37) 56 (112)
White other 8 (5) 15 (10) 18 (12) 14 (27)
Mixed 2 (1) 6 (4) 8 (5) 5 (10)
Black/Black British 3 (2) 3 (2) 2 (1) 3 (5)
Asian/Asian British 11 (7) 10 (7) 6 (4) 9 (18)
Other 8 (5) 3 (2) 3 (2) 5 (9)
Number of sexual partners, % (n)
1 64 (42) 56 (38) 60 (39) 60 (119)
2 23 (15) 22 (15) 23 (15) 23 (45)
3 8 (5) 15 (10) 9 (6) 11 (21)
4+ 6 (4) 7 (5) 8 (5) 7 (14)
Mean (SD) 1.6 (1.18) 1.8 (1.10) 1.7 (1.12) 1.7 (1.13)
Number of contactable sexual partners, % (n)
1 71 (47) 62 (42) 68 (44) 67 (133)
2 17 (11) 19 (13) 15 (10) 17 (34)
3 6 (4) 15 (10) 12 (8) 11 (22)
4+ 6 (4) 4 (3) 5 (3) 5 (10)
Mean (SD) 1.5 (1.18) 1.6 (0.94) 1.5 (0.89) 1.6 (1.01)
Contactable partners
Arm Standard
N=102
APTHotline
N=111
APTPharmacy
N=100
Total
N=313
Relationship to the index, %(n)
Cohabiting/married/civil partnership 3 (3) 14 (15) 7 (7) 8 (25)
Steady but not cohabiting 48 (49) 38 (42) 44 (44) 43 (135)
Sex once 30 (31) 23 (26) 27 (27) 27 (84)
Have sex from time to time 3 (3) 12 (13) 12 (12) 9 (28)
Ex-partner 12 (12) 8 (9) 6 (6) 9 (27)
Just met for the first time 4 (4) 5 (6) 4 (4) 4 (14)
APT, accelerated partner therapy.
Table 2 Treatment and notification of contactable partners by randomisation arm
Standard
N=102
% (n)
APTHotline
N=111
% (n) AOR* (95% CI)
APTPharmacy
N=100
% (n) AOR* (95% CI)
Total
N=313
% (n)
Notification
Notified 74 (75) 68 (75) 0.91 (0.48–1.73) 66 (66) 0.90 (0.65–1.27) 69 (216)
Not notified 4 (4) 11 (12) 3 (3) 6 (19)
Unknown (index followed-up) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown (index not followed-up) 23 (23) 22 (24) 33 (33) 25 (78)
Treatment
Treated 45 (46) 35 (39) 0.64 (0.35–1.18) 46 (46) 1.06 (0.78–1.45) 42 (131)
Not treated 11 (11) 5 (5) 7 (7) 7 (23)
Unknown (index followed-up) 22 (22) 37 (41) 15 (15) 25 (78)
Unknown (index not followed-up) 23 (23) 23 (26) 32 (32) 26 (81)
Treated partners only, %(n) Standard, N=46 Hotline, N=39 Pharmacy, N=46 Total, N=131
Location of treatment
APTHotline N/A 21 (8) N/A 6 (8)
APTPharmacy N/A N/A 30 (14) 11 (14)
GP 28 (13) 21 (8) 7 (3) 18 (24)
GUM clinic 46 (21) 26 (10) 35 (16) 36 (47)
Other 11 (5) 8 (3) 9 (4) 9 (12)
Unknown (Index followed-up) 15 (7) 26 (10) 20 (9) 20 (26)
*OR for partner notified relative to any other outcome, adjusted for index age and ethnicity, relative to standard arm.
APT, accelerated partner therapy; GP, general practitioner; GUM, genitourinary medicine.
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arm. No partners were known to have attended a clinic for an
HIVor syphilis test.
Process evaluation
Community healthcare professionals found the web tool easy to
use as it provided a user-friendly interface on which to docu-
ment the PN discussion. However, seeking informed consent at
an emotionally difﬁcult time for the index patient was perceived
to be difﬁcult and in some cases led to healthcare professionals
failing to offer the study.
Although all services were highly supportive of the research,
they experienced difﬁculty implementing the study and recruit-
ment was suboptimal. Both CASH services underwent major
organisational changes and all the general practices were
affected by wide-ranging national changes in service commis-
sioning during the recruitment period and research was not
prioritised. We centralised recruitment by enabling the research
health adviser to offer the study to eligible patients by tele-
phone. This resulted in a rapid increase in recruitment rates.
As regards acceptability to participants, follow-up interviews
with index patients and sex partners showed high levels of
acceptability of the APT interventions.19 No harmful clinical
incidents were reported.
CONCLUSIONS
We developed and tested two novel replicable, feasible, accept-
able and safe APT models for use in primary care settings,
which met General Medical Council guidance8 on remote pre-
scribing. However, individual recruitment to the trial was difﬁ-
cult. Overall, a similar proportion of partners were reported as
treated in all three arms of the trial, in each case fewer than
half, and the addition of APT interventions did not appear to
improve outcomes. Uptake of the adjunct interventions was
poor and most PN was achieved via standard methods, rather
than via APT. The online patient and data management tool was
acceptable to clinical staff and feasible for the referral of
patients for PN support and outcome measurement.
Women reported numbers of sex partners comparable to
women attending specialist sexual health services9 and the
majority of sex partners were contactable. No sex partners
reported receiving HIV and syphilis testing, though a small
number of sex partners in APT arms returned a postal test kit
for chlamydia and gonorrhoea. Despite good levels of index
patient follow-up, return of postal test kits for reinfection
testing 6 weeks post treatment was low.
Achieving effective PN in primary care is problematic11 13 14 21
but the importance of improving the effectiveness of PN as a
strategy for improving population control of C. trachomatis is
well recognised.7 There are challenges to the comparison of our
data with other studies. We report PN outcomes primarily per
partner (although we include outcomes per index patient), as
we feel that this is a helpful measure of the potential for preven-
tion of further transmission.22 However, current guidelines for
PN, and newly available surveillance reports in England, con-
tinue to focus on outcomes per index patient.23 Nevertheless,
the suboptimal rates of PN described here are superior to those
reported in similar settings.11 13 23
Historically, non-specialist settings have not had a routinely
available PN infrastructure and PN outcomes have rarely been
measured or recorded. The provision of a formal PN service
and the presence of researchers are both likely to produce a sub-
stantial ‘Hawthorne effect’24 by normalising the discussion of
PN. This may alone empower an index patient to achieve
patient referral.
Our previous study of APT in specialist sexual health settings
used partner focused outcome measures and suggested that APT
could improve PN outcomes as compared with standard patient
referral.9 10 However, there were important differences in the
design, inclusion criteria and exact nature of the interventions
which make direct comparisons difﬁcult. Our earlier study
allowed index patients to select the method of PN they thought
would best suit each partner whereas this study randomised
patients. In routine clinical practice, index patients choose from
a range of PN options and we believe that randomising patients
to a single intervention may not be the optimal design for sensi-
tive interventions such as PN.25
Here, time to sex partner treatment was similar across all
arms, whereas in our previous APT study, sex partners in APT
arms achieved treatment faster than those receiving standard
PN.9 This difference is likely to be explained by poor uptake of
APT interventions within the intervention arms.
Implementation of a pilot trial of this size, with multiple
recruitment sites, at a time of wide ranging health service
upheaval26 was extremely difﬁcult. We had to reduce our ori-
ginal sample size to provide more realistic recruitment require-
ments for each service and support recruitment centrally. Our
primary outcome was largely index reported rather than sex
partner veriﬁed, which introduces uncertainty around the
robustness of outcome ascertainment. Indexes may not have
known whether their sex partners received STI testing as well as
treatment. ‘Standard PN’ could be enhanced or simple patient
referral depending on the service and or the healthcare profes-
sional involved. This may have made it hard to demonstrate an
added beneﬁt of the APT interventions.
Although we included a biological outcome, in practice, it did
not prove useful as index postal retesting had low uptake
despite telephone reminders. We do not know whether the part-
ners of women who declined to take part were more or less
likely to be treated. Our sample could therefore be biased in
either direction with respect to the target population of index
patients and partners.
The care pathways we developed, using a novel online patient
referral and data management tool, provide a feasible and
acceptable infrastructure for onward referral of patients diag-
nosed with STIs in primary care, to receive PN support. These
could usefully form part of a portfolio of PN modalities which
collectively improve overall PN outcomes. The low uptake of
STI testing and HIV testing is notable, and suggests that modes
of PN which do not require direct engagement with a clinical
service offering comprehensive testing may be unsuitable for
higher risk populations. While in the future this could be
addressed through postal self-sampling for a wider range of
infections, they are not suitable either for individuals or for
populations who have been identiﬁed as higher risk, such as
men who have sex with men (MSM) and MSM partners of het-
erosexual women.27
Overall, PN outcomes were superior to previously reported
PN measures in similar settings but an in-depth understanding
of reasons for poor uptake of the interventions in this study will
be important for future PN research irrespective of the setting.
A cluster, non-consented (Zelen) design in which whole services
are randomised to the offer of an APT intervention is likely to
circumvent many of the difﬁculties faced by this trial. Although
controversial, this approach has been undertaken in the ﬁeld of
chlamydia screening.28 29 Research should also be undertaken
to explore how to identify and reach higher risk partners in
primary care settings who may beneﬁt from a more comprehen-
sive range of sexual health services.
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Key messages
▸ We developed two novel primary care accelerated partner
therapy (APT) models, showing them to be acceptable, feasible,
regulation compliant and capable of achieving acceptable
outcomes within a pilot randomised controlled trial (RCT).
▸ Addition of these interventions to standard partner
notiﬁcation (PN) did not result in a difference between arms,
but overall PN uptake was higher than previously reported in
similar settings.
▸ Recruitment to an individually randomised trial proved
challenging and full evaluation is likely to require
service-level randomisation.
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